Capsule Endoscopy Market (2026-2036)
The global capsule endoscopy market is estimated to be USD 0.65 billion in 2026. This market is expected to reach USD 1.68 billion by 2036, growing at a CAGR of 10.0% during the forecast period 2026–2036.
- Published
- Jun 2026
- Pages
- 265
- Format
- PDF + Excel
- Report ID
- MRHC - 1042083
- Base year
- 2025
- 2026 · ESTIMATED
- $650.0M
- 2036
- $1.68B
- CAGR 2026–2036
- 10.0%
2025 baseline · 2026–2036 forecast at 10.0% CAGR · hover a bar for the value
Key highlights
The global capsule endoscopy market is projected to reach USD 1.68 billion by 2036, growing at a CAGR of 10.0% during the forecast period 2026–2036.
North America is expected to dominate the global market in 2026, driven by high prevalence of gastrointestinal disorders and early adoption of AI-assisted diagnostic platforms.
Asia Pacific is projected to witness the fastest growth, fueled by rapid modernization of diagnostic infrastructure and innovation in magnetically controlled capsule technology.
By product type, the small bowel capsule endoscopy segment is expected to hold the largest share in 2026, as the clinical gold standard for non-invasive visualization of the small intestine.
By application, the obscure gastrointestinal bleeding (OGIB) segment is expected to account for the largest share in 2026, given the capsule's unique ability to identify sources of unexplained bleeding.
By end user, the hospitals & diagnostic centers segment is expected to hold the largest share in 2026, as the primary setting for specialized capsule diagnostic procedures.
Key players operating in the global market include Medtronic plc, Olympus Corporation, IntroMedic Co., Ltd., Ankon Medical Technologies, and CapsoVision, Inc.
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2036 |
| Market Size (2026) | USD 650.0 million |
| Market Size (2036) | USD 1.68 billion |
| CAGR (2026–2036) | 10.0% |
| Format | PDF, Excel & Cloud Portal · 265 pages |
| Segments Covered | By Product Type · By Application · By End User |
| Key Companies | Medtronic plc, Olympus Corporation, IntroMedic Co., Ltd., Ankon Medical Technologies, CapsoVision, Inc., Fujifilm Holdings Corporation, Jinshan Science and Technology, RF System lab, Check-Cap Ltd., PillCam, Given Imaging, Shangxian Medical, ZRE, AccuRead, AnX Robotics, Chongqing Jinshan Science & Technology, Shenzhen Jifu Medical Technology, IntroMedic (MiroCam), CapsoCam (CapsoVision), Medtronic (PillCam COLON) (US) |
Report overview
Segments covered: product type, application, end user.
The global capsule endoscopy market represents a transformative segment of the gastrointestinal diagnostic industry, providing a patient-friendly, non-invasive alternative to traditional endoscopy for visualizing the entire digestive tract. Capsule endoscopy involves the use of a swallowable, pill-sized camera that captures high-resolution images as it travels naturally through the gastrointestinal system, offering unparalleled access to the small bowel—an area traditionally difficult to reach. This market is primarily driven by the rising global incidence of gastrointestinal diseases such as Crohn's disease and colorectal cancer, the increasing patient preference for non-invasive procedures, and the rapid integration of artificial intelligence (AI) to streamline image analysis. According to clinical guidelines from the World Endoscopy Organization (WEO) and the American Society for Gastrointestinal Endoscopy (ASGE), capsule endoscopy is an essential diagnostic tool for obscure gastrointestinal bleeding and inflammatory bowel disease monitoring. As the technology evolves toward magnetically controlled navigation and enhanced battery life, the market is expected to witness significant expansion, supported by the shift toward decentralized, outpatient diagnostic care.
Report infographic
Market dynamics
8 factors across 4 forcesIncreasing Patient Preference for Non-Invasive and Sedation-Free Diagnostic Procedures
A major driver for the capsule endoscopy market is the significant patient preference for non-invasive diagnostic solutions that do not require sedation or invasive tube insertion. According to the World Health Organization, colorectal cancer accounted for approximately 1.9 million new cases globally in 2022, making it the third most commonly diagnosed cancer worldwide and underscoring the need for improved patient participation in gastrointestinal screening programs. Furthermore, the Crohn's & Colitis Foundation estimates that more than 10 million people worldwide are living with inflammatory bowel disease (IBD), many of whom require repeated gastrointestinal evaluation throughout their lifetime. Capsule endoscopy offers a comfortable, swallow-and-go alternative that enables patients to continue their daily activities while capturing high-quality diagnostic images of the gastrointestinal tract. The absence of sedation, reduced procedural discomfort, and minimal recovery time contribute to higher patient acceptance, particularly for small bowel evaluation, colorectal cancer screening, and long-term monitoring of Crohn's disease, thereby supporting sustained market growth.
Integration of Artificial Intelligence and Machine Learning in Image Interpretation
The integration of artificial intelligence (AI) and machine learning (ML) is revolutionizing the capsule endoscopy market by addressing the primary challenge of long reading times. A single capsule procedure can generate over 50,000 images, making manual review a time-consuming task for gastroenterologists. AI-assisted reading platforms can now automatically identify and prioritize suspicious lesions, bleeding sources, and mucosal abnormalities, significantly reducing the time required for diagnosis while improving accuracy. This technological evolution is enhancing the clinical efficiency of capsule endoscopy, making it more scalable and attractive for healthcare providers, thereby driving market adoption.
Table of contents
12 chapters · 111 sections · 265 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Product Type | Small bowel capsule endoscopy | Colon capsule endoscopy |
| By Application | Obscure gastrointestinal bleeding (OGIB) | Inflammatory bowel disease (IBD) |
| By End User | Hospitals & diagnostic centers | Ambulatory surgical centers (ASCs) |
By Product Type
- The small bowel capsule endoscopy segment is expected to hold the largest share of the global capsule endoscopy market in 2026.
- This dominant position is substantiated by its status as the clinical gold standard for non-invasive visualization of the small intestine, an area that is largely inaccessible to traditional endoscopy.
- Its established role in diagnosing obscure GI bleeding and Crohn's disease, backed by robust reimbursement, ensures its market leadership.
- However, the colon capsule endoscopy segment is projected to register the highest CAGR during the forecast period.
- The increasing clinical validation of colon capsules for colorectal cancer screening and the rising patient demand for non-invasive alternatives to traditional colonoscopy are driving this segment's rapid growth.
By Application
- The obscure gastrointestinal bleeding (OGIB) segment is expected to hold the largest share in 2026.
- This leadership is driven by the unique ability of capsule endoscopy to provide high-resolution imaging of the entire small bowel, making it the most effective tool for identifying the source of unexplained bleeding.
- However, the inflammatory bowel disease (IBD) segment is projected to grow at the fastest CAGR during the forecast period.
- The rising global prevalence of Crohn's disease and the increasing use of capsule endoscopy for non-invasive monitoring of mucosal healing and disease extent are accelerating growth in this application area.
By End User
- The hospitals & diagnostic centers segment is expected to hold the largest share in 2026.
- These facilities are the primary setting for capsule endoscopy due to the requirement for specialized recording equipment and expert interpretation by gastroenterologists.
- However, the ambulatory surgical centers (ASCs) segment is projected to register the highest CAGR during the forecast period.
- The ongoing trend toward moving diagnostic procedures to outpatient settings to improve efficiency and reduce costs is driving the rapid adoption of capsule endoscopy in ASCs, which can handle high patient volumes with lower overhead costs.
Geographic analysis
North America
Largest shareNorth America is expected to dominate the global capsule endoscopy market in 2026. This leading position is attributed to the high prevalence of gastrointestinal disorders, well-established reimbursement models, and the early adoption of AI-assisted diagnostic platforms. The region benefits from a highly developed healthcare infrastructure and a strong presence of leading players like Medtronic and CapsoVision. Key companies operating in the North America market are Medtronic plc, CapsoVision, Inc., and Olympus Corporation. Largest Share: North America
Asia-Pacific
Fastest growthThe Asia-Pacific region is projected to witness the fastest growth in the global capsule endoscopy market, with a CAGR of 11.8% during the forecast period. This rapid expansion is driven by the large patient population, increasing healthcare expenditure, and the rapid modernization of diagnostic facilities in countries like China, Japan, and India. The region is also a hub for innovation in magnetically controlled capsule technology. Key companies operating in the Asia Pacific market are Olympus Corporation, Ankon Medical Technologies, IntroMedic Co., Ltd., and Fujifilm Holdings Corporation. Fastest Growing: Asia-Pacific
Competitive landscape
The global capsule endoscopy market is characterized by a mix of major global medical technology corporations and specialized innovative players focusing on imaging and AI. Competition is primarily focused on improving image resolution, battery life, and field of view, while simultaneously developing AI-powered software to automate image analysis. Key players are investing in magnetically controlled navigation systems that allow for active examination of the stomach and other organs. There is also a significant emphasis on developing specialized capsules for the colon and esophagus to expand the diagnostic reach of the technology. Strategic developments often involve partnerships between hardware manufacturers and AI software developers to provide comprehensive, end-to-end diagnostic solutions. Furthermore, manufacturers are increasingly focusing on clinical validation studies to support the inclusion of capsule endoscopy in national screening programs and to secure favorable reimbursement, which is critical for maintaining market leadership in an increasingly patient-centric diagnostic field.
- Medtronic plc
- Olympus Corporation
- IntroMedic Co., Ltd.
- Ankon Medical Technologies
- CapsoVision, Inc.
- Fujifilm Holdings Corporation
- Jinshan Science and Technology
- RF System lab
- Check-Cap Ltd.
- PillCam · Medtronic
- Given Imaging · Medtronic
- Shangxian Medical
- ZRE · Shenzhen Zhaori
- AccuRead
- AnX Robotics
- Chongqing Jinshan Science & Technology
- Shenzhen Jifu Medical Technology
- IntroMedic (MiroCam)
- CapsoCam (CapsoVision)
- Medtronic (PillCam COLON) (US)
Frequently asked questions
The global market is estimated at USD 0.65 billion in 2026, with a projected growth to USD 1.68 billion by 2036, at a CAGR of 10.0%.
Cite this report
Meticulous Research. (2026). Capsule Endoscopy Market - Global Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MRHC - 1042083). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/capsule-endoscopy-market-6766